drugset / Trial / NCT00891475

Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients

NCT00891475

Phase 1/2 Completed 114 enrolled Kidney Cancer Research Bureau
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate efficacy and safety of Radiofrequency ablation in metastatic renal cell carcinoma patients with primary tumor less than 5 cm before medical treatment. Ablation may allow for reduced morbidity and may increase the likelihood of patients receiving systemic therapy.

Timeline

Start
2008-05
Primary completion
2010-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule 50 mg Oral

Indications